Aura Biosciences (AURA)
(Delayed Data from NSDQ)
$7.59 USD
+0.20 (2.71%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $7.58 -0.01 (-0.13%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AURA 7.59 +0.20(2.71%)
Will AURA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AURA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AURA
UnitedHealth (UNH), Amedisys Clear Merger Hurdle With Asset Sale
Teladoc (TDOC) Harnesses AI for Diabetes Care, Stock Rises 6.7%
AURA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Brookdale (BKD) Sees 31 Months of Y/Y Occupancy Growth Streak
Wall Street Analysts See a 162.63% Upside in Aura Biosciences (AURA): Can the Stock Really Move This High?
Wall Street Analysts Think Aura Biosciences, Inc. (AURA) Could Surge 174.29%: Read This Before Placing a Bet
Other News for AURA
Aura Energy Becomes Substantial Shareholder
Aura Energy Issues Shares and Advances Discussions
Aura Energy Expands Market Presence on ASX
Aura Energy Seeks Quotation for New Shares
Aura Energy Issues New Unquoted Options